What do systematic reviews say?

Quinolone vs aminoglycosides

The review found no eligible studies for this question.

• Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs quinolones

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sinonasal debridement vs no debridement

• Sinonasal debridement versus no debridement for the postoperative care of patients undergoing endoscopic sinus surgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 58 participants
  Low

Topical quinolone vs intramuscular gentamicin

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs oral amoxicillin‐clavulanic acid combination

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antifungal vs placebo/no treatment

The review found no eligible studies for this question.

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 38 participants
  Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 784 participants
  High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 265 participants
  Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 105 participants
  Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 766 participants
  Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 105 participants
  Low

Intervention not reported

The intervention showed no clear difference in health‐related quality of life scores, measured by SF‐36 (range 0 to… (low certainty).

• Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps 2014 · Cochrane Headline outcomes only
  MD 0.6
  1 study · 95 participants
  Low